Celprogen Introduces a Novel Pharmacological Inhibitor CEP1430 for Human Pancreatic Cancer Patients

AACR Annual Meeting 2015

TORRANCE, Calif.--()--Celprogen Inc., a leader in the Stem Cell Research and Therapeutics industry for the development of stem cell technologies for regenerative medicine, today announced that they have developed a novel pharmacological Inhibitor CEP1430 synthetic molecule that is capable of inhibiting the growth and proliferation of the human pancreatic cancer tumor. This molecule can be administrated by the following methods: intravenous and intra-peritoneal. The molecule CEP1430 will be presented at the American Association for Cancer Research Annual Meeting in Philadelphia, Tuesday, April 21, 2015, 1:00 PM - 5:00 PM; Therapeutics Targeting Cancer Stem Cells.

The present invention relates to targeting the Cancer Stem Cell (CSC) and Circulating Tumor Cells (CTCs) population within the human pancreatic tumor. The novel pharmacological inhibitor molecule CEP1430 has been developed and optimized by Celprogen utilizing cancer stem cell drug discovery high throughput screening technology. This technology has generated approximately 10 lead compounds for targeted cancer therapy for pancreatic cancer patients. Our preclinical results show that CEP1430 is efficacious against Pancreatic CSC and CTCs without adverse effects at doses tested. CEP1430 reduced the tumor volume in the treated group by 80-90% in comparison to control.

About Celprogen Inc.

Celprogen Inc. is a global Stem Cell Research & Therapeutics company which is developing a proprietary portfolio of unique therapeutics products and life science research tools that includes genetic engineering technologies, stem cell technologies for regenerative medicine, as well as bio-engineering products for tissue & organ transplants. Headquartered in Torrance, California, Celprogen is committed to the research, development, and manufacture of quality Stem Cell, Cancer Stem Cell and Primary Cell Culture products to serve our global community. Additional information about Celprogen is available at http://www.celprogen.com.

Contacts

For additional information on the product line contact:
Celprogen Inc.
Jay Sharma
310-542-8822
info@celprogen.com
www.celprogen.com

Release Summary

Celprogen introduces CEP1430, a novel inhibitor for the Human Pancreatic Cancer tumor. CEP1430 is a selective Pancreatic Cancer Stem Cell inhibitor that reduced the tumor volume by 80-90%.

Contacts

For additional information on the product line contact:
Celprogen Inc.
Jay Sharma
310-542-8822
info@celprogen.com
www.celprogen.com